ACO REACH: An Innovative Step Towards Health Equity

By Danélia Botes

October 29, 2023

Understanding ACO REACH and its Impact

Launched in January 2023, Accountable Care Organisation Realising Equity, Access, and Community Health (ACO REACH), initiated by the Centers for Medicare and Medicaid Services (CMS), has taken a strategic leap towards equity in healthcare. The model is designed to promote health equity through payment model design, data collection on social drivers of health, and financial incentives linked to equity.

A key feature of ACO REACH is the Health Equity Benchmark Adjustment (HEBA). This adjustment allows for increases or decreases in participants’ financial benchmarks based on the beneficiaries they serve. The goal? To remove the disincentives to serve marginalised populations by acknowledging the extra costs of caring for these groups.

Changes to HEBA Calculations in 2024

As we move into 2024, Medicare is taking on board stakeholder feedback and revising its approach to HEBA calculations. This change is significant, as it marks one of the first attempts to alter financial targets based on non-medical factors.

The way HEBA scores are calculated will also undergo changes. Currently, the HEBA is based on measures of individual beneficiary income and area-level social need. However, from next year, CMS will incorporate beneficiaries’ state ADI, a measure that ranks the social need in a beneficiary’s neighbourhood against the need in other neighbourhoods across a given state.

The implications of these changes are substantial. They represent a pragmatic way to improve policymakers’ ability to identify individuals with low-income and high health-related need.

In conclusion, ACO REACH is one of the first models to reflect a national call to action for health care stakeholders to go beyond traditional approaches to value-based payment and address equity. 

Reference url

Recent Posts

Alzheimer's Treatments
                 

Alzheimer’s Treatments: Evaluating Emerging Therapies and NICE’s Stance on Lecanemab

🌟 #SyenzaNews: The landscape of Alzheimer’s treatment is evolving with new drugs on the horizon. While NICE recently found lecanemab’s benefits too small to justify its cost, promising treatments like donanemab, remternetug, and blarcamesine show potential. Learn more about these emerging therapies and their impact on Alzheimer’s care. 💊🧠
#AlzheimersResearch #HealthcareInnovation #PharmaNews #DementiaCare

Preventing falls among older adults
          

Preventing Falls Among Older Adults: A Vital Healthcare Imperative

🧓👵 Falls among the elderly are a significant concern. Read our latest insight to explore the awareness and preventive measures of fall risks among older adults in Buraidah, Qassim. Discover key findings and strategies to reduce fall incidents.

#SyenzaNews #ElderlyCare #FallPrevention #HealthAwareness #PatientSafety

Let’s work together to raise awareness and implement effective strategies to prevent falls among older adults.

Hevolution Foundation ageing research
             

In Saudi Arabia, the Hevolution Foundation is Reshaping Ageing Research

The quest for healthier ageing is gaining momentum! 🌟 Discover how the Hevolution Foundation is transforming longevity research with a $1 billion annual commitment. Their groundbreaking work is set to reshape the future of healthspan for everyone. 🌍💡

#SyenzaNews #AgeingResearch #Healthspan #Longevity #HevolutionFoundation #HealthcareInnovation #FutureOfHealth

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

JOIN NEWSLETTER




SERVICES

© 2024 Syenza™. All rights reserved.